What do medical sources say about Glyburide during pregnancy?

1st Trimester: Human evidence about glyburide use in the first trimester is limited. A 2003 review of ten studies of oral diabetes medicines found no significant increase in major birth defects or newborn deaths overall, but it could not identify effects for glyburide alone. A 2017 review also found that first-trimester studies often grouped different medicines together. The current DailyMed label says there are no adequate controlled pregnancy studies and says to use glyburide only if clearly needed. ADA guidance says glyburide is not a first-line medicine for diabetes during pregnancy, but it does not provide a first-trimester birth-defect estimate. Ask your provider about your situation. 2nd Trimester: For gestational diabetes, ADA identifies insulin as first-line treatment and says glyburide is not a first-line medicine because it crosses the placenta and may not meet blood sugar goals. In the 2018 INDAO randomized trial of 914 women diagnosed between 24 and 34 weeks, a combined newborn outcome occurred in 27.6% of the glyburide group and 23.4% of the insulin group. The trial did not establish that glyburide was no worse than insulin for these outcomes. A 2026 review of randomized trials found more newborn low blood sugar and large birth size with glyburide than with insulin. These findings mainly come from gestational-diabetes treatment studies, not estimates for every reason glyburide may be used. Ask your provider about your situation. 3rd Trimester: ADA reports that glyburide crosses the placenta and is linked with more newborn low blood sugar in gestational-diabetes studies. DailyMed reports prolonged, severe low blood sugar lasting 4 to 10 days in newborns whose mothers took a sulfonylurea at delivery; it says to stop glyburide at least two weeks before the expected delivery date. In a small study of 46 mother-infant samples, glyburide was found in cord blood and higher levels were linked with newborn low blood sugar. Average cord-blood levels fell below 5 ng/mL after 24 hours from the last dose, but that study does not replace the label’s timing instruction. Ask your provider about your situation.

What do medical sources say about Glyburide while breastfeeding?

LactMed says limited studies found negligible or undetectable glyburide levels in milk and advises watching breastfed infants for low blood sugar, with glucose checks if there is concern. In a small 2005 study, glyburide was not detected in milk; one fully breastfed infant exposed at steady state had a normal blood glucose reading. A separate high-dose case involved a preterm infant with severe low blood sugar at birth; glyburide was later found in the infant’s blood and the mother’s milk, so pregnancy exposure could not be separated from milk exposure. A 2026 review found limited transfer data and inconsistent breastfeeding guidance. DailyMed says it is unknown whether glyburide enters human milk and notes a possible low blood sugar risk for nursing infants. Ask your provider about your situation.

Where do sources disagree on Glyburide in pregnancy or breastfeeding?

How specifically do guidelines limit glyburide for gestational diabetes? The ADA Standards of Care 2026 say insulin is first-line in the United States and glyburide is not a first-line medicine for diabetes in pregnancy because it crosses the placenta and has concerns about offspring outcomes. ACOG says insulin is the recommended medication during pregnancy, while noting that an oral medicine may be prescribed in some cases; its FAQ does not name glyburide. The ADA gives glyburide-specific guidance based on placental transfer and pregnancy studies. The ACOG FAQ gives general patient guidance and does not identify which oral medicines it means. The sources agree that insulin is recommended, but differ in how specifically they discuss oral medicines. ACOG’s general statement is not a glyburide-specific endorsement. The ADA’s drug-specific caution and trial evidence support a guidance rating rather than a claim that all oral medicines are equivalent.

Back to search

Glyburide

Medication

Sulfonylurea antidiabetic

Pregnancy

First-trimester evidence is limited and does not isolate glyburide well. Gutzin et al. (2003) pooled 10 studies of oral hypoglycemic agents in women with type 2 diabetes; major malformations were not significantly higher (OR 1.05, 95% CI 0.65 to 1.70), and neonatal death was not significantly higher (OR 1.16, 95% CI 0.67 to 2.00). The authors said the studies did not provide enough detail to identify effects by individual drug and were heterogeneous. Shepherd et al. (2017) likewise noted that first-trimester studies often grouped agents together. For gestational diabetes, the 2018 INDAO randomized trial enrolled 914 women diagnosed at 24 to 34 weeks. Its composite of macrosomia, newborn low blood sugar, or jaundice occurred in 27.6% with glyburide and 23.4% with insulin; it failed to establish noninferiority. Bouchghoul et al. (2020) analyzed usable delivery samples from 46 mother-infant pairs: the fetal-to-maternal concentration ratio was 62%, cord levels fell below a mean 5 ng/mL after 24 hours from the last dose, and higher cord levels were associated with newborn hypoglycemia; no newborn in that sample was admitted to intensive care or treated for hypoglycemia. A 2026 meta-analysis of randomized trials found higher macrosomia and neonatal hypoglycemia rates with glyburide than insulin, with moderate-to-high certainty for those outcomes. The 2025 SWIFT prospective cohort followed 809 mother-child pairs to ages 5 to 11 years; after adjustment for maternal prepregnancy BMI, glyburide itself was not significantly associated with childhood obesity (aRR 1.14, 95% CI 0.91 to 1.43), while early GDM diagnosis was associated with obesity in both treatment groups. An April 2026 FAERS analysis identified 164 glyburide pregnancy reports and 17 signals, including newborn hypoglycemia and congenital anomalies; spontaneous reports do not establish incidence or causation, and the authors called for prospective confirmation.

Breastfeeding

Feig et al. (2005) measured milk and blood levels after single doses in eight women and daily doses in five women taking glyburide or glipizide. Glyburide was not detected in milk in either study; three infants were fully breastfed at steady state, including one exposed to glyburide, and their glucose levels were normal. LactMed (revised May 15, 2026) summarizes limited evidence as showing negligible milk levels and advises monitoring for signs of low blood sugar. Myngheer et al. (2014) reported one mother with KCNJ11-related neonatal diabetes taking 85 mg/day, later increased to 90 mg/day. Her preterm infant had severe hyperinsulinemic hypoglycemia at birth, needed intravenous glucose for eight days, and had measurable glyburide in infant serum; the mother’s milk also contained glyburide. The authors considered milk a possible contributor to ongoing exposure, but the report cannot separate milk exposure from transfer during pregnancy. Richardson et al. (2026) found clinical transfer data for only five of 20 diabetes drugs, including glyburide, and concluded that published breastfeeding recommendations were inconsistent and often based on limited evidence.

How specifically do guidelines limit glyburide for gestational diabetes?

Source A says: The ADA Standards of Care 2026 say insulin is first-line in the United States and glyburide is not a first-line medicine for diabetes in pregnancy because it crosses the placenta and has concerns about offspring outcomes. (American Diabetes Association: Standards of Care in Diabetes, 2026, Management of Diabetes in Pregnancy)
Source B says: ACOG says insulin is the recommended medication during pregnancy, while noting that an oral medicine may be prescribed in some cases; its FAQ does not name glyburide. (ACOG: Gestational Diabetes FAQ)
Why they differ: The ADA gives glyburide-specific guidance based on placental transfer and pregnancy studies. The ACOG FAQ gives general patient guidance and does not identify which oral medicines it means.
Other sources: SMFM’s 2018 statement, reaffirmed in 2024, calls metformin a reasonable first-line alternative to insulin for some GDM patients; it does not specifically endorse glyburide. (SMFM: Pharmacological Treatment of Gestational Diabetes Statement)
What the evidence shows overall: The sources agree that insulin is recommended, but differ in how specifically they discuss oral medicines. ACOG’s general statement is not a glyburide-specific endorsement. The ADA’s drug-specific caution and trial evidence support a guidance rating rather than a claim that all oral medicines are equivalent.

Glyburide timing before delivery

Source A says: The current DailyMed label says glyburide, if used during pregnancy, should be discontinued at least two weeks before the expected delivery date and reports prolonged severe newborn hypoglycemia with sulfonylureas taken at delivery. (DailyMed: Glyburide tablets, Teva (current generic label))
Source B says: Bouchghoul et al. found cord blood glyburide concentrations decreased steeply after the last maternal dose; the mean cord concentration was below 5 ng/mL after 24 hours in 46 usable samples. (Bouchghoul et al. 2020: Transplacental transfer and neonatal hypoglycemia)
Why they differ: The label gives a precautionary timing instruction. The small ancillary study measured drug concentrations and newborn outcomes; it did not test whether a shorter interruption is clinically appropriate.
What the evidence shows overall: The study supports placental transfer and a relationship between cord concentration and newborn hypoglycemia, but it does not establish a replacement for the label’s two-week instruction.

How much is known about glyburide in human milk?

Source A says: The current DailyMed label says it is not known whether glyburide is excreted in human milk and notes that nursing-infant hypoglycemia may occur. (DailyMed: Glyburide tablets, Teva, Nursing Mothers section)
Source B says: LactMed says limited data indicate milk levels are negligible and recommends monitoring breastfed infants for low blood sugar. (LactMed: Glyburide)
Why they differ: The label describes the class warning and lack of a formal label conclusion, while LactMed summarizes small human milk-transfer studies published after the label text.
Other sources: The 2026 systematic review found sparse clinical transfer evidence and inconsistent published recommendations for diabetes medicines during breastfeeding. (Richardson et al. 2026: Systematic review of diabetes medicines in breastmilk)
What the evidence shows overall: The small Feig study found no detectable milk glyburide and normal glucose in one fully breastfed infant exposed at steady state. A separate high-dose case cannot distinguish milk exposure from pregnancy exposure. The evidence remains limited, so the summary preserves both the label uncertainty and LactMed’s monitoring guidance.

Last reviewed 2026-10-16

Independent check 2026-10-16

Not yet clinician-reviewed

Ask your provider about your situation.

Similar medications

Glipizide

Glyburide

Glyburide — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications